Glenmark Pharmaceuticals (GLENMARK) Share Price Falls 2% Today

Published:   28 September 2026 at 10:23:33 AM IST

Glenmark Pharmaceuticals Share Price was lower in today’s session, with Glenmark Pharmaceuticals trading at Rs 2,335.35, down 2% from the previous close of Rs 2,383. The company’s market capitalisation stood at Rs 67,254.14 crore, placing it in the Large Cap category. The move is relevant because Glenmark Pharmaceuticals Share Price today is being watched alongside the broader Glenmark Pharmaceuticals stock news flow, even though the supplied data does not establish a company-specific catalyst for the decline. For readers tracking Glenmark Pharmaceuticals share price news, the key facts are the current price, the day’s percentage fall, and the company’s valuation and sector context. Univest is presenting the event strictly from the verified numbers supplied in the workflow.

Within today’s session, Glenmark Pharmaceuticals Share Price moved between Rs 2,398.80 and Rs 2,330. The stock opened at Rs 2,398.80, matched that level as the day’s high, and touched the low of Rs 2,330 before closing at Rs 2,335.35. The session therefore left Glenmark Pharmaceuticals Share Price update readers with a lower close than both the open and the previous close. Univest notes the exact turnover of Rs 1.26 crore as a factual market-value figure. Since the supplied data confirms the price event but does not establish a company-specific catalyst, the focus stays on price action, fundamentals, sector positioning and peer comparison.

Glenmark Pharmaceuticals (GLENMARK) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,335.35
Previous Close	Rs 2,383
Today's Move	-Rs 47.65 (-2%)
Open	Rs 2,398.8
High	Rs 2,398.8
Low	Rs 2,330
Turnover	Rs 1.26 crore
Market Capitalisation	Rs 67,254.14 crore
Market Cap Category	Large Cap

Glenmark Pharmaceuticals Share Price today reflected a decline of Rs 47.65, or 2%, from the previous close of Rs 2,383 to Rs 2,335.35. The day opened at Rs 2,398.80, which was also the high, and then moved to a low of Rs 2,330 before settling near that lower end. That sequence shows a session that ended below the open, below the previous close and close to the intraday low. For a reader following Glenmark Pharmaceuticals share price fall, the important point is the exact path of the move, not an assumed reason.

The stock’s market capitalisation of Rs 67,254.14 crore places it in the Large Cap category, and the exact turnover reported for the day was Rs 1.26 crore. Those facts define the day’s trading snapshot without adding any unverified interpretation. In Glenmark Pharmaceuticals stock analysis terms, the verified data confirms a negative day for price, but it does not by itself explain the trigger. That makes the stock part of Glenmark Pharmaceuticals stock news and Glenmark Pharmaceuticals News Today only on the basis of the observed session data. From here, the discussion shifts to fundamentals, valuation and sector context, which can help frame Glenmark Pharmaceuticals Share Price in a broader research setting.

Glenmark Pharmaceuticals (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 67,254.14 crore
P/E Ratio	37.41x
P/B Ratio	6.14x
ROE	14.1%
ROCE	20.35%
EPS	Rs 63.7
Book Value Per Share	Rs 388.43
Dividend Yield	0.1%

EPS is Rs 63.70, which tells readers how much earnings are attributable to each share. Book value is Rs 388.43 per share, which shows the accounting net worth behind each share, while dividend yield is 0.10%, a small historical payout metric relative to the current price. In Glenmark Pharmaceuticals Share Price terms, these figures indicate that today’s decline should be viewed alongside a business that still carries a premium valuation compared with the wider industry set. The supplied financial metrics support Glenmark Pharmaceuticals Stock Analysis by giving a clear valuation and profitability backdrop, rather than a directional call. Univest highlights these numbers because they matter to anyone comparing Glenmark Pharmaceuticals Share Price Today with the company’s longer-term operating profile.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	37.41x
Benchmark Median P/E	32.87x
Benchmark Average P/E	49.63x
Benchmark P/E Range	3.46x to 735.85x
Company P/B Ratio	6.14x
Benchmark Median P/B	2.85x
Benchmark Average P/B	4.33x
Company ROE	14.1%
Benchmark Median ROE	11.48%
Benchmark Average ROE	10.04%
Company ROCE	20.35%
Benchmark Median ROCE	13.17%
Benchmark Average ROCE	12.82%
Company Market Capitalisation	Rs 67,254.14 crore
Benchmark Median Market Cap	Rs 732.57 crore
Benchmark Average Market Cap	Rs 14,043.26 crore

Glenmark Pharmaceuticals operates in Healthcare, within the Pharmaceuticals & Drugs industry. The sector benchmark supplied here covers the same industry and includes 204 companies, which gives a broad comparison base for Glenmark Pharmaceuticals Share Price and Glenmark Pharmaceuticals Share Price Today. Glenmark’s P/E of 37.41 is above the industry median of 32.87 and below the industry average of 49.63, while its P/B of 6.14 is above the median of 2.85 and above the average of 4.33. Those numbers show how the company sits versus a wide industry sample, without needing any outside assumptions.

On profitability, Glenmark’s ROE of 14.10% is above the industry median of 11.48% and above the average of 10.04%, while ROCE of 20.35% is above the industry median of 13.17% and above the average of 12.82%. The sector benchmark also shows a market-cap median of Rs 732.57 crore and an average of Rs 14,043.26 crore, while Glenmark’s market capitalisation is Rs 67,254.14 crore. That places Glenmark well above the median and average company size in this sample. For readers following Glenmark Pharmaceuticals stock news, the sector context explains why Glenmark Pharmaceuticals Share Price remains important in the healthcare universe: the company’s valuation and return metrics are not isolated numbers, but part of a wider industry comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,44,716.74	36.77	5.14	14.85	19.11
Divi's Laboratories	DIVISLAB	2,55,115.31	87.22	14.44	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,613.38	86.94	21.13	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,19,899.96	26.57	4.45	19.69	21.39
Cipla	CIPLA	1,12,875.68	33.49	3.21	11.83	16

Glenmark Pharmaceuticals Share Price can also be viewed against listed peers in the same industry. Glenmark’s P/E of 37.41 is higher than Zydus Lifesciences at 26.57, Dr. Reddy’s Laboratories at 31.16 and Cipla at 33.49, but lower than Divi’s Laboratories at 87.22, Torrent Pharmaceuticals at 86.94, Laurus Labs at 98.88 and Mankind Pharma at 50.06. That places Glenmark in the middle-to-upper range on earnings multiple within this peer set.

On returns, Glenmark’s ROE of 14.10% is below Lupin’s 27.11% and Torrent’s 26.76%, but above Cipla’s 11.83% and Dr. Reddy’s 11.69%. ROCE at 20.35% is stronger than Sun Pharmaceutical Industries at 19.11%, Cipla at 16.00% and Dr. Reddy’s at 13.75%, though slightly below Lupin at 28.86% and Zydus Lifesciences at 21.39%. In market-cap terms, Glenmark at Rs 67,254.14 crore sits below the larger healthcare names in this peer set, while still well above the industry median. That is the core peer context for Glenmark Pharmaceuticals Share Price news and Glenmark Pharmaceuticals stock analysis.

Why Investors Are Watching Glenmark Pharmaceuticals

• Glenmark Pharmaceuticals Share Price fell 2% today to Rs 2,335.35 from Rs 2,383.
• The session range was Rs 2,398.80 to Rs 2,330, with closing price near the day’s low.
• Market capitalisation stood at Rs 67,254.14 crore, which places the company in the Large Cap category.
• P/E is 37.41, P/B is 6.14, ROE is 14.10% and ROCE is 20.35%.
• The sector benchmark covers 204 pharmaceuticals and drugs companies, giving a wide comparison base.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is classified in Healthcare and the Pharmaceuticals & Drugs industry. In this article, Univest is using only the verified company-level and industry-level figures supplied by the workflow. The stock’s market capitalisation is Rs 67,254.14 crore, and the company is part of a broad listed universe where peers range from large healthcare names to mid-sized pharmaceutical companies. For readers following Glenmark Pharmaceuticals Stock News or Glenmark Pharmaceuticals Share News, the current session matters because it combines a same-day price fall with a detailed valuation snapshot. Glenmark Pharmaceuticals Share Price therefore sits in a setting where sector comparison, peer comparison and fundamentals all matter together.

Track Glenmark Pharmaceuticals Share Price on Univest

Use Glenmark Pharmaceuticals (GLENMARK) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

Readers can track Glenmark Pharmaceuticals Share Price on Univest for live price updates, financial ratios, shareholding pattern, 52-week levels and market insights. Univest brings together Glenmark Pharmaceuticals stock news, Glenmark Pharmaceuticals share price update and company analysis in one place, helping users follow the stock with verified data and a clear market context.

Frequently Asked Questions

Why did Glenmark Pharmaceuticals Share Price fall today?

Ans.  The verified data shows Glenmark Pharmaceuticals Share Price fell 2% to Rs 2,335.35. The supplied information confirms the price event, but it does not establish a company-specific catalyst for the decline.

What was Glenmark Pharmaceuticals Share Price today?

Ans.  Glenmark Pharmaceuticals Share Price today closed at Rs 2,335.35 after moving down Rs 47.65 from the previous close of Rs 2,383. The stock opened at Rs 2,398.80 and touched a low of Rs 2,330.

What is Glenmark Pharmaceuticals market capitalisation?

Ans.  Glenmark Pharmaceuticals has a market capitalisation of Rs 67,254.14 crore. That places it in the Large Cap category in the supplied data and well above the industry sample median of Rs 732.57 crore.

How does Glenmark Pharmaceuticals compare with sector peers?

Ans.  Glenmark Pharmaceuticals has a P/E of 37.41, higher than Zydus Lifesciences, Dr. Reddy’s and Cipla, but below Divi’s Laboratories and Torrent Pharmaceuticals. Its ROCE of 20.35% is also above several peers.

What do Glenmark Pharmaceuticals fundamentals show?

Ans.  Glenmark Pharmaceuticals reports EPS of Rs 63.70, book value of Rs 388.43 and dividend yield of 0.10%. These figures provide context for Glenmark Pharmaceuticals Share Price and help frame the stock’s valuation and earnings profile.